Needham Maintains Buy on Starling Oncology, Raises Price Target to $9
Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.
Stocks · News reference
Starling Oncology, Inc. Announces Third Quarter 2026 Financial Results Release Date
Starling Oncology, Inc. (NASDAQ: STLN) has scheduled the release of its third quarter 2026 financial results for November 5, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Starling Oncology shares are trading higher after the company reported a year-over-year decrease in Q2 loss per share and increase in sales results.
Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $161.282 million in